Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters a 30‑day option to
View HTML
Toggle Summary Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
- Data to highlight etrasimod, Arena's orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of autoimmune diseases -
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th
SAN DIEGO , March 27, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi , the Company's President and Chief Executive Officer, will present
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer
SAN DIEGO , March 20, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced the appointment of Dr. Preston Klassen , M.D., M.H.S.
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
- Clinical Data from Multiple Phase 2 Development Programs Expected in 2017 -
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference
SAN DIEGO , March 8, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi , the Company's President and Chief Executive Officer will present
View HTML
Toggle Summary Arena Pharmaceuticals to Provide Corporate Update and Release Fourth Quarter and Full-Year 2016 Financial Results on Tuesday, March 14, 2017
SAN DIEGO , March 06, 2017 (GLOBE NEWSWIRE) -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), today announced that the Company will provide a corporate update and release its fourth quarter and full-year 2016 financial results on Tuesday, March 14, 2017 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Three New Members to Board of Directors
SAN DIEGO , Feb. 14, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the appointment of three new members to the company's Board of Directors.  Jayson Dallas , M.D., Oliver Fetzer , Ph.D., and Garry A. Neil , M.D. have joined as independent directors.  The new
View HTML
Toggle Summary Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017
SAN DIEGO , Feb. 9, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Scott Lee and Professor Tanja Kühbacher will present data on etrasimod (APD334) at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) - Inflammatory Bowel Diseases 2017
View HTML
Toggle Summary Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally
Arena Expects to Receive $23 Million of Cash Payments and Over $80 Million of Potential Cost Relief and Will Continue to Focus on Its Clinical Programs
View HTML